Ingalls & Snyder LLC’s AbbVie ABBV Stock Holding History

Ingalls & Snyder LLC’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-16,700	Closed	-$2.26M	–	465
2021 Q4	$2.26M	Hold	16,700	–	–	0.1%	149
2021 Q3	$1.8M	Hold	16,700	–	–	0.08%	170
2021 Q2	$1.88M	Buy	16,700 +100	+0.6%	+$11.3K	0.08%	173
2021 Q1	$1.8M	Buy	16,600 +6,700	+68%	+$717K	0.08%	172
2020 Q4	$1.06M	Buy	9,900 +6,600	+200%	+$634K	0.05%	214
2020 Q3	$289K	Buy	+3,300	New	+$311K	0.02%	303

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Ingalls & Snyder LLC's ABBV Position: Q2 2026 in Review

Ingalls & Snyder LLC reduced its AbbVie (ABBV) stake by 2.7% in Q2 2026, selling an estimated $811K and leaving 135,858 shares worth $34.2M. The position accounts for 0.93% of the portfolio, ranked #19.

Ingalls & Snyder LLC first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Ingalls & Snyder LLC held 135,858 shares of AbbVie worth $34.2M as of Q2 2026.
Ingalls & Snyder LLC sold 3,769 AbbVie shares in Q2 2026, an estimated $811K.
AbbVie made up 0.93% of Ingalls & Snyder LLC's portfolio in Q2 2026, its #19 holding.
Ingalls & Snyder LLC first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Ingalls & Snyder LLC's 13F filing for Q2 2026, filed 14 Aug 2026.